摘要
近年来已有较多应用度普利尤单抗治疗大疱性类天疱疮的报道.度普利尤单抗(Dupilumab)可特异性结合白细胞介素4受体亚基a(IL-4Ra),阻断IL-4和IL-13的信号转导,抑制B细胞的增殖、减少嗜酸性粒细胞募集、抑制Th2相关趋化因子功能,从而改善大疱性类天疱疮患者皮损及瘙痒.本文就度普利尤单抗治疗类天疱疮的可能机制、临床疗效、不良反应等作一综述.
Abstract
In recent years,there have been many reports on the use of Dupilumab in the treat-ment of bullous pemphigoid.Dupilumab specifically binds to the subunit alpha of interleukin 4 re-ceptor(IL-4Rα),blocking the signal transduction of interleukin(IL)-4 and IL-13,inhibiting the proliferation of B cells,reducing the recruitment of eosinophils,and suppressing the function of Th2-related chemotactic factors,thereby improving skin lesions and itching of patients.This arti-cle reviews the potential mechanisms,clinical efficacy,and adverse reactions of Dupilumab in the treatment of bullous pemphigoid.
基金项目
云南省科技厅科技计划项目(202301AY070001-248)
国家科技期刊平台
NSTL
万方数据